User:WatchesTheStars/Lore:Interdyne

FACTION

Interdyne Pharmaceuticals

Other Names: Dyne, IDP Related Pages: Ghost Role Policy Related Lore: SolFed, Nova Sector Languages: Sol CommonAnd when contact was established, the Admiral waved at the screen and said, "Mi parolas la lingvon de la Homines!" - I speak the language of Mankind. A simplified mix of Esperanto and Modern Latin, and the only recognized official language of the Sol Federation. This peculiar constructed language became popular during SolFed's earliest days, and was almost entirely overtaken by other popular tongues - it became widespread through heavy-handed political maneuvering with the help of corporate bureaucrats and other undesirables. Nowadays, it's a near-universal tongue and a must-know for any sentient being that plans to leap forward into space. Contributors: Template:Contributor/WatchesTheStars

Many well-known clinics and treatment facilities on the frontier are supplied by Interdyne Pharmaceuticals; a Sovereign Corporation specializing in advanced medicine, biotech, and synthetic drug development. While widely respected for breakthroughs like Sansufentanyl, critics question their ethics and blame them for conditions they now profit from treating. Interdyne maintains ties with nearly every major power in the sector, including Nanotrasen, SolFed, and even Syndicate-linked interests.

Interdyne Pharmaceuticals

Interdyne Pharmaceuticals is a Sovereign medical conglomerate with holdings that stretch from Core Sector capitals to the most remote edge-world colonies. In the Core, their name is stamped on hospitals, research towers, and entire pharmaceutical districts; on the frontier, it's printed on emergency kits, cryo-sleep injectors, and the last dose of stabilizer keeping a colonist alive.

Their reputation is built not on ideology or allegiance, but clinical ubiquity. Interdyne doesn’t plant flags or claim sectors; it offers licensing, supplies, and medical infrastructure, with the same practiced detachment whether the client flies SolFed banners or Syndicate colors. So long as they can pay, Interdyne delivers.

Their flagship drug, Sansufentanyl, is widely credited with slowing- though not curing- the spread of Hereditary Manifold Sickness, a condition particularly common among early colonization bloodlines. The fact that Interdyne developed the treatment, holds exclusive production rights, and may have played a role in the disease’s emergence is a conspiracy whispered more often than spoken aloud, and one the company shows no interest in acknowledging.

Where other Sovereign Corporations pursue expansion through territory, firepower, or anomaly exploitation, Interdyne’s dominance comes through treatment dependencies, embedded systems, and regulated exclusivity. Whether in a clean Core clinic or a half-frozen frontier triage pod, Interdyne is there- not to lead, not to govern, but to ensure no one else holds the prescription pad.

History

Interdyne Pharmaceuticals emerged sometime after the creation of faster-than-light travel on Terra, during the first serious wave of interstellar colonization. It was not born from idealism, nor from any humanitarian push to heal the expanding population, but from a sharp-eyed interest in the growing medical demands of deep-space life, and how best to profit from them.

Unlike other early corporations that sought prestige through terraforming or exploration, Interdyne carved its place through research, specifically into the then-mysterious rise of Hereditary Manifold Sickness (HMS). While other institutions scrambled to understand the sickness or dismissed it as colonial myth, Interdyne moved fast, establishing specialized labs and funneling resources into human genetic profiling. The result was Sansufentanyl, the first viable long-term treatment for HMS symptoms, and a drug that would define their legacy.

The speed of this breakthrough raised eyebrows. The drug was unnervingly well-matched to the sickness. Critics argued that Interdyne may have known more than they let on- or worse, played a role in the disease's emergence. But as Interdyne’s profits surged and their laboratories became the gold standard for bio-clinical precision, those critics either faded from public view or stopped speaking entirely. As a Sovereign Corporation, Interdyne faced no formal investigations and issued no apologies.

With Sansufentanyl under exclusive license, Interdyne grew fast, "too fast", some said, mirroring the explosive trajectory of Nanotrasen. They outpaced rival biotech firms, absorbed competitors, and embedded themselves in Core Sector hospitals before the public ever realized they had a monopoly. When their market dominance reached a threshold, Sovereign status followed, not through political leverage, but sheer economic gravity. It was no longer viable for governments or corporate interests to not do business with Interdyne.

Yet as the company expanded, so too did its internal philosophy. The cold profiteering that defined its founding years began to refine itself into a doctrine of detachment. In the modern era, Interdyne does not present itself as a benevolent healer, nor a malevolent schemer. It simply offers medicine to those who need it, at scale, at cost, and without moral entanglement.

Today, Interdyne’s presence is split. In the Core, it is surgical in its presentation: clean clinics, towering hospitals, pristine autodocs, and boardrooms lined with white marble and reinforced glass. On the Frontier, it is no less precise- but markedly more somber. Facilities are often compact and utilitarian, focused on maximum efficiency over comfort. Outposts operate with reduced staff, limited amenities, and strict protocol adherence, prioritizing clinical output over personnel well-being. Field stations may be spartan, but they are clean, controlled, and meticulously maintained, reflecting a corporate ethos that sees luxury as waste when treating patients hundreds of lightyears from oversight. Interdyne doesn’t need to impress out there. It only needs to function, and it does, relentlessly.

To the average person, Interdyne is just another Sovereign logo stamped on the pill bottle or clinic wall. Its name is as common as running water- and just as unquestioned.

Branches

Central Administration

At the core of Interdyne’s sprawling operations is Central Administration, the governing body responsible for corporate continuity, strategic policy, and internal regulation. Unlike the theatrical “executive boards” of other Sovereign Corporations, Central Administration maintains a deliberately sterile image. There are no public-facing personalities, no press conferences, and rarely any names attached to decisions. Policies arrive signed only with branch codes and embedded approval hashes; faceless, authoritative, and final.

Central Administration is headquartered in the Core Sectors, operating from a clinical vertical complex known simply as Facility Zero. It is believed to house the primary legal and financial divisions, high-level biomedical archives, and executive arbitration rooms. Access to the facility is restricted even among Interdyne staff; most interaction with Central Administration comes through automated directives and cold correspondence, not personal audiences.

This branch oversees:

• Sovereign compliance and legal immunity
• Budget allocation and internal restructuring
• Security doctrine and personnel clearance levels
• Strategic product launches (e.g., new drug rollouts, system-wide licensing)
• Blackbook trials and unlisted field projects

Central Administration does not rule Interdyne through ideology or charisma, it simply ensures the machine keeps running, free of interruption or interference. It is not known for innovation or outreach. Its role is continuity.

Research

The Research Division of Interdyne Pharmaceuticals is the foundation of the company’s scientific advancement, driving forward everything from drug development to biotechnical experimentation. Operated through a network of compartmentalized Clinical Nodes, the division is structured to maintain strict internal silos, where most researchers work in isolation, unaware of broader objectives. All intellectual property and outcomes are owned in full by Interdyne; public disclosure is both rare and tightly managed by Central Administration.

Interdyne’s most public achievement- the creation of Sansufentanyl- originated here, but that compound represents only a fragment of the division’s capabilities.

Two of its more closely guarded focus areas are Xenobiology and Virology.

In Xenobiology, Interdyne specializes in the cultivation and study of non-terrestrial lifeforms with unusual regenerative or mutagenic properties. The most notable of these are colloquially referred to as “slimes,” adaptable, bio-reactive organisms that can be selectively bred for undisclosed purposes. Whether used in synthetic organ scaffolding, biochemical harvesting, or something more experimental, these creatures are considered high-value research assets. Handling protocols are extensive- in the Core that is.

Virology, meanwhile, extends far beyond traditional immunology. Interdyne’s virologists are tasked with identifying, dissecting, and in many cases designing pathogenic agents. While officially labeled as preventive research, this branch has been repeatedly accused of experimenting with controlled outbreaks, tailored immunodeficiencies, and synthetic viral models with unclear applications. None of these claims have been substantiated in any court and likely never will be.

While Core-based Clinical Nodes operate under rigid procedural oversight, Frontier research sites follow a different doctrine. There, the Research Division functions with a degree of freedom rarely seen in corporate science. Protocols are fluid. Oversight is minimal. Projects forbidden in the Core are quietly greenlit, given space to breathe and evolve. Researchers assigned to Frontier postings are often selected for their risk tolerance, creativity, and discretion.

The result is a branch that appears controlled and clean from the outside, but behind locked lab doors- particularly on the edge of settled space- pushes science in directions few others are willing to.

Private Security

Interdyne Pharmaceuticals does not maintain a traditional in-house security force. Instead, all physical protection, facility defense, and risk response services are outsourced to vetted Private Military Contractors (PMCs) under tightly negotiated service contracts. This approach ensures that Interdyne can maintain legal and ethical distance from the use of force, while still preserving operational integrity across Core and Frontier installations.

PMCs contracted by Interdyne vary depending on the location and threat profile. Core Sector sites typically employ low-visibility, compliance-focused firms trained in asset preservation and non-lethal containment, often chosen for their professionalism and ability to blend seamlessly into Interdyne’s sterile environment. In contrast, Frontier deployments may be handled by less conventional contractors, including former Syndicate-affiliated outfits, mercenary collectives, or sovereign-aligned enforcement groups selected for flexibility and effectiveness rather than public image.

While Interdyne does not take responsibility for the actions of its contractors, all PMC personnel operating on Interdyne grounds are required to follow Interdyne’s on-site compliance standards, and are monitored via embedded reporting systems. This layered approach allows Interdyne to respond quickly to sabotage, espionage, or biosecurity breaches without directly implicating its own staff or administration.

Internally, this security model is referred to as Tiered Detachment, the principle that violence and enforcement should be performed at a contractual remove from the corporation’s intellectual core. Force is a tool, not a signature, and Interdyne ensures that it remains just that.

Critics argue this system enables deniability and shields the company from accountability during unethical operations. Interdyne’s response remains consistent: “Our role is medicine. Security is a service.”

Pharmaceutics

The Pharmaceutics Division is the most publicly visible and commercially dominant branch of Interdyne Pharmaceuticals. It oversees the manufacture, refinement, and distribution of Interdyne’s vast medicinal portfolio; including everything from basic first-aid treatments and combat stims to proprietary gene therapy kits and chronic condition suppressants. Across both the Core and the Frontier, it is Interdyne’s compounds that fill emergency kits, surgical tanks, and prescription pads.

Operations within this branch are highly automated, supported by orbital fabs, subterranean synthesis labs, and ship-mounted mobile processing units. Product distribution is tightly stratified: premium-tier treatments are reserved for Sovereign clients and coreworld clinics, while ruggedized or off-brand variants are packaged for frontier markets. Despite aesthetic differences, all flow from the same carefully protected synthesis chains.

Interdyne’s power, however, lies not just in what it produces but in how it sells. The company holds strategic shares in dozens of smaller medical and distribution firms, quietly embedding itself across supply chains without appearing as the sole supplier. These affiliate companies such as DeForest, a well-known Core-facing logistics and pharmacy network often sell Interdyne-developed treatments at lowered public rates, appearing more accessible and consumer-friendly. While these firms take a modest cut, Interdyne profits twice: once through product sales, and again through shareholder returns from the very companies "undercutting" them.

This tactic allows Interdyne to:

• Maintain market dominance without brand oversaturation

• Shape pricing trends while appearing competitively undercut

• Expand into restricted or politically sensitive regions via proxies

• Offload risk and liability while retaining economic control

In the Frontier, the Pharmaceutics Division operates leaner. Facilities are streamlined, often staffed by minimal crews or automated entirely, with distribution overseen by remote logistics networks. Some compounds distributed in these zones have not undergone full Core-standard trials- though packaging may suggest otherwise.

Though Interdyne’s innovation begins in research, it is through the Pharmaceutics Division’s controlled spread and hidden partnerships that their influence becomes inescapable. In clinics where no one knows who made the drug, Interdyne still collects the profit.

Notable Products

Work in Progress: Footer subject to change at a moment's notice. Do not take a red link's presence, struck-through or otherwise, as confirmation (or denial) of their canonicity.

Nova Sector Lore
	Common Species	Humans, Tiziran, Unathi, Moths, Ethereals, Azulae, Slime Hybrids, Teshari, Synthetic Humanoids (and assorted robots), Pod Persons, Hemophages, Xenomorphic Hybrid,
	Other Species	Genemodders (Felinids, Ice Walkers, Dwarf), Ashwalkers, Snailpersons, Ordoht (Formerly Skrell), Plasmamen, Flypeople, Vox (Primalis et al), Tajaran, Vulpkanin, Rouges (Abductorkin), Miscellaneous Species, Dullahans, Employee Golems, Changelings
	Nanotrasen	Nanotrasen, Central Command, Emergency Response Corps
	External Groups	The Syndicate (Gorlex, Tiger Cooperative, DS-2, Syndicate Manifestos), Interdyne Pharmaceutics, Cargo, The Spider Clan, Heliostatic Coalition, The Void Imperium
	Nova	The Nova Sector, IndecipheresLavaland, volcanic mining place., FreyjaIcebox and Snowglobe station frozen moon., BoletusSerenity Mushroomoon.
	Concepts	Bluespace, Plasma, Faster Than Light Travel, Resonance ("Souls"), Death
	SolFed	SolFed, Sol in 2565, The SolFed Armed Forces